The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10317 malaria professionals are enjoying the free benefits of MalariaWorld today

chloroquine

Solution behavior of hematin under acidic conditions and implications for its interactions with chloroquine

May 3, 2010 - 14:58 -- Patrick Sampao
Author(s): 
Maria P. Crespo, Leann Tilley and Nectarios Klonis
Reference: 
Journal of Biological Inorganic Chemistry

The analysis reveals that aqua-ligated FP has a low propensity to self-associate and that the predominant self-associated species are homodimeric hydroxide-ligated FP and heterodimeric aqua/hydroxide-ligated FP.

Open Access | Chloroquine and Its Derivatives Exacerbate B19V-Associated Anemia by Promoting Viral Replication

April 29, 2010 - 13:21 -- Kabogo Ndegwa
Author(s): 
Claudia Bönsch, Christoph Kempf, Ivo Mueller, Laurens Manning, Moses Laman, Timothy M. E. Davis, Carlos Ros
Reference: 
PLoS Negl Trop Dis 4(4): e669

Our data strongly suggest that 4-aminoquinoline drugs and their metabolites exacerbate B19V-associated anemia by promoting B19V replication. Consideration should be given for choosing a non-4-aminoquinoline drug to partner artemisinin compounds in combination antimalarial therapy.

Medical Condition: 

Open Access | Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial

April 22, 2010 - 13:34 -- Kabogo Ndegwa
Author(s): 
Awab G, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee S, Day NP, Singhasivanon P, White NJ, Kaker F
Reference: 
Malaria Journal 2010, 9:105 (21 April 2010)

Chloroquine remains an efficacious treatment for the treatment of vivax malaria in Afghanistan. In a setting where radical therapy cannot be administered, dihydroartemisinin-piperaquine provides additional benefit in terms of post-treatment prophylaxis, reducing the incidence of recurrence from 4-8 weeks after treatment. Trial Registration The trial was registered at ClinicalTrials.gov under identifier NCT00682578.

Country: 
Medical Condition: 

Open Access | Plasmodium falciparum spermdine synthase inhibition results in unique perturbation-specific effects observed on transcript, protein and metabolite levels

April 14, 2010 - 13:29 -- Patrick Sampao
Author(s): 
John VW B., Linda ., et al.
Reference: 
BMC Genomics 2010, Vol 11:235

This study details the malaria parasite's response to PfSpdSyn inhibition on the transcriptomic, proteomic and metabolic levels. 

Medical Treatment: 

High chloroquine treatment failure rates and predominance of mutant genotypes associated with chloroquine and antifolate resistance among falciparum malaria patients from the island of Car Nicobar, India

April 8, 2010 - 12:39 -- Kabogo Ndegwa
Author(s): 
MK Das, V Lumb, P Mittra, SS Singh, AP Dash, YD Sharma
Reference: 
Journal of Antimicrobial Chemotherapy April 2, 2010

There is a predominance of chloroquine- and antifolate-resistant P. falciparum malaria in Car Nicobar, requiring an alternative antimalarial drug treatment policy, such as implementation of artesunate combination therapy (ACT), for this island.

Country: 
Province Or State: 
Medical Condition: 
Medical Treatment: 

Open Access | Research: Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu

April 7, 2010 - 12:38 -- Kabogo Ndegwa
Author(s): 
Kinzer MH, Chand K, Basri H, Lederman ER, Susanti AI, Elyazar I, Taleo G, Rogers WO, Bangs MJ, Maguire JD
Reference: 
Malaria Journal 2010, 9:89 (6 April 2010)

The only in vivo malaria drug efficacy trial thus far published from the Republic of Vanuatu showed chloroquine/sulphadoxine-pyrimethamine combination therapy for P. falciparum and chloroquine alone for P. vivax to be highly efficacious.

Country: 
Medical Condition: 

Early transcriptional response to chloroquine of the Plasmodium falciparum antioxidant defence in sensitive and resistant clones

March 18, 2010 - 13:01 -- Patrick Sampao
Author(s): 
Fátima Nogueira, Amalia Diez, Azar Radfar, Susana Pérez-Benavente, Virgilio E. do Rosario, Antonio Puyet, José M. Bautista
Reference: 
Acta Tropica, Volume 114, Issue 2, May 2010, Pages 109-115

To gain insight into early parasite stress response, mRNA expression profiles were determined for a set of 10 antioxidant defence genes in synchronized CQ-sensitive (3D7) and CQ-resistant (Dd2) clones under transient IC50 CQ-exposure (Dd2, 200 nM; 3D7, 14 nM).

Medical Treatment: 

Monitoring of failure of chloroquine treatment for Plasmodium vivax using polymerase chain reaction in Sanliurfa province, Turkey

March 17, 2010 - 10:46 -- Ingeborg van Schayk
Author(s): 
Fuat Dilmec, M. Ali Kurcer, Feridun Akkafa & Zeynep Simsek
Reference: 
Parasitology Research, Volume 106, Number 4 / March, 2010 : 783-788

Our target was to determine the Plasmodium species in the southeast region of Turkey and the therapeutic efficacy of CQ used in the treatment of malaria.

Technology: 
Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Dynamics of pfcrt alleles CVMNK and CVIET in chloroquine-treated Sudanese patients infected with Plasmodium falciparum

March 14, 2010 - 10:30 -- Ingeborg van Schayk
Author(s): 
Nahla B Gadalla, Salah Eldin Elzaki, Ebtihal Mukhtar, David C Warhurst, Badria El-Sayed, Colin J Sutherland
Reference: 
Malaria Journal 2010, 9:74 (12 March 2010)

Parasite resistance to the anti-malarial drug chloroquine is common in eastern Sudan. Dynamic within-host changes in the relative abundance of both sensitive and resistant Plasmodium falciparum parasites were examined in a cohort of chloroquine-treated patients presenting with uncomplicated falciparum malaria, using a novel allele-specific quantitative approach.

Country: 
Medical Treatment: 

p53 is required for chloroquine-induced atheroprotection but not insulin sensitization

March 9, 2010 - 12:02 -- Ingeborg van Schayk
Author(s): 
Babak Razani, Chu Feng and Clay F. Semenkovich
Reference: 
J. Lipid Res., doi:10.1194/jlr.M003681

ATM, mutated in ataxia telangiectasia, is critical for the genotoxic stress response and its deficiency is associated with accelerated atherosclerosis and insulin resistance in humans and mice. The anti-malarial drug chloroquine activates ATM signaling and improves metabolic phenotypes in mice.

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - chloroquine